Karyopharm Therapeutics (KPTI) in Focus: Stock Goes Down 5.2%

Zacks

Karyopharm Therapeutics, Inc. (KPTI) saw a big move last session, as the company’s shares fell by over 5% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for KPTI, as the stock is now up nearly 7% since Jun 24.

Although this slump was obviously disappointing, current year earnings consensus for this clinical-stage pharmaceutical company has moved higher over the past few weeks. This suggests that the recent slump might be a temporary blip on the radar for KPTI. So make sure to keep an eye on this stock going forward to see if yesterday’s price decline is confirmed by more weakness, or if it can rebound in the weeks ahead.

KPTI currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Some better-ranked stocks in the same sector include Synergy Pharmaceuticals, Inc. (SGYP), Ariad Pharmaceuticals Inc. (ARIA) and Endo International plc (ENDP). While Synergy Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), Ariad Pharmaceuticals and Endo International hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>



KARYOPHARM THERAPEUTICS INC (KPTI): Free Stock Analysis Report

SYNERGY PHARMACEUTICALS DE (SGYP): Free Stock Analysis Report

ARIAD PHARMACEUTICALS INC (ARIA): Free Stock Analysis Report

ENDO INTERNATIONAL PLC ORD (ENDP): Free Stock Analysis Report


Zacks Investment Research

View Comments (0)